Current research status of transarterial therapies for hepatocellular carcinoma  

作　　者：Mao-Ting Zhou Peng Zhang Qi Mao Xiao-Qin Wei Lin Yang Xiao-Ming Zhang 

机构地区：[1]Department of Radiology,Interventional Medical Center,Science and Technology Innovation Center,The Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,Sichuan Province,China [2]School of Medical Imaging,North Sichuan Medical College,Nanchong 637000,Sichuan Province,China

出　　处：《World Journal of Gastrointestinal Oncology》2024年第9期3752-3760,共9页世界胃肠肿瘤学杂志（英文版）（电子版）

基　　金：Project of City-University Science and Technology Strategic Cooperation of Nanchong City,No.20SXQT0324。

摘　　要：With continuous advancements in interventional radiology,considerable progress has been made in transarterial therapies for hepatocellular carcinoma(HCC)in recent years,and an increasing number of research papers on transarterial therapies for HCC have been published.In this editorial,we comment on the article by Ma et al published in the recent issue of the World Journal of Gastrointestinal Oncology:“Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable HCC”.We focus specifically on the current research status and future directions of transarterial therapies.In the future,more studies are needed to determine the optimal transarterial local treatment for HCC.With the emergence of checkpoint immunotherapy modalities,it is expected that the results of trials of transarterial local therapy combined with systemic therapy will bring new hope to HCC patients.

关 键 词：Hepatocellular carcinoma Transarterial therapies Transarterial chemoembolization Hepatic artery infusion chemotherapy Transarterial embolization Transarterial radioembolization 

分 类 号：R735.7[医药卫生—肿瘤]